Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770681 | 0.91 | SMN1; SMN2 (0.46) | KDM4EALDH1A1SMN1; SMN2HTTHRH3 | |
| SCHEMBL4666227 | 0.87 | DRD2 (0.47) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL4232566 | 0.86 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL4666177 | 0.85 | SLC5A7 (0.46) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL4934783 | 0.84 | SLC6A3 (0.56) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL4934782 | 0.84 | SLC6A3 (0.56) | KDM4EALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL4667823 | 0.84 | SMN1; SMN2 (0.46) | KDM4EALDH1A1SMN1; SMN2HRH3OPRK1 | |
| SCHEMBL4930039 | 0.83 | MAPK14 (0.58) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL4227919 | 0.81 | PRMT6 (0.50) | SMN1; SMN2MEN1KMT2AHRH3CARM1 | |
| SCHEMBL4770428 | 0.81 | MCHR1 (0.48) | KDM4EALDH1A1HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| EP-1891065-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006130075-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | claimed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1891065-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006130075-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | MCHR1, MCHR2, HCRTR1 | KDM4E 2600/4885ALDH1A1 1070/4885SMN1; SMN2 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.